Alessandra Magnani

Alessandra Magnani

Auto-generated profile, based on publicly available information

Alessandra Magnani

HPC Italia S.r.l., Via Francesco Ferrucci 17/A, 20145, Milan, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JRJean-Antoine Ribeil
Jean-Antoine Ribeil
SHSalima Hacein-Bey-Abina
Salima Hacein-Bey-Abina
EPEmmanuel Payen
Emmanuel Payen
AMAlessandra Magnani
Alessandra Magnani
MSMichaela Semeraro
Michaela Semeraro
MCMarina Cavazzana
Marina Cavazzana
Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the complex cellular abnormalities and challenges in achieving effective, persistent inhibition of polymerization of hemoglobin S. We describe our first patient treated with lentiviral vector–mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells. Adverse events were consistent with busulfan conditioning. Fifteen months after treatment, the level of therapeutic antisickling β-globin remained high (approximately 50% of β-like–globin chains) without recurrence of sickle crises and with correction of the biologic hallmarks of the disease. (Funded by Bluebird Bio and others; HGB-205 ClinicalTrials.gov number, NCT02151526.)

1 September 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AMAlessandra Magnani
Alessandra Magnani
PBPauline Brosselin
Pauline Brosselin
JBJulien Beauté
Julien Beauté
NVNathalie de Vergnes
Nathalie de Vergnes
RMRichard Mouy
Richard Mouy
NMNizar Mahlaoui
Nizar Mahlaoui

8 October 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
Angelo RavelliAngelo Ravelli
Angelo Ravelli
GVGiulia C. Varnier
Giulia C. Varnier
SOSheila Oliveira
Sheila Oliveira
ECEsteban Castell
Esteban Castell
OAOlga Arguedas
Olga Arguedas
AMAlberto Martini
Alberto Martini
Objective: We undertook this study to test the hypothesis that in the International League of Associations for Rheumatology (ILAR) classification of juvenile idiopathic arthritis (JIA), patients with similar characteristics can be classified into different categories. We sought to investigate whether antinuclear antibody (ANA)–positive patients having disease in the ILAR categories of oligoarthritis, rheumatoid factor–negative polyarthritis, psoriatic arthritis, and undifferentiated arthritis share homogeneous features and to compare these features with those of ANA‐negative patients having the same categories of disease.Methods: We identified JIA patients who had been followed up during a 22‐year period. ANA positivity was defined as ≥2 positive results at a titer of ≥1:160. Demographic and clinical features were recorded retrospectively and compared between ANA‐positive and ANA‐negative patients.Results: Of a total of 971 patients, 711 were ANA positive, 149 were ANA negative, and 111 had an indeterminate ANA status. Patients with indeterminate ANA status were excluded. ANA‐positive patients in the different ILAR categories were similar in terms of age at disease presentation, female‐to‐male ratio, and frequency of asymmetric arthritis and iridocyclitis. Compared with ANA‐positive patients, the ANA‐negative group was older at disease presentation and had a lower prevalence of females, a lower frequency of iridocyclitis and asymmetric arthritis, a greater number of affected joints over time, and a different pattern of arthritis. The close relationship between the presence of ANAs and younger age at disease presentation, female predominance, asymmetric arthritis, development of iridocyclitis, lower number of affected joints over time, and lack of hip involvement was also confirmed by multivariate and multiple correspondence analysis.Conclusion: Our findings substantiate the hypothesis that ANA‐positive patients classified into different JIA categories by current ILAR criteria constitute a homogeneous patient population.

22 February 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
CLChantal Lagresle-Peyrou
Chantal Lagresle-Peyrou
FLFrançois Lefrère
François Lefrère
EMElisa Magrin
Elisa Magrin
JRJean-Antoine Ribeil
Jean-Antoine Ribeil
OROriana Romano
Oriana Romano
MCMarina Cavazzana
Marina Cavazzana
Sickle cell disease is characterized by chronic anaemia and vaso-occlusive crises, which eventually lead to multi-organ damage and premature death. Haematopoietic stem cell transplantation is the only curative treatment but it is limited by toxicity and poor availability of HLA-compatible donors. A gene therapy approach based on the autologous transplantation of lentiviral-corrected haematopoietic stem and progenitor cells was shown to be efficacious in one patient. However, alterations of the bone marrow environment and the red blood cells9 properties hamper the harvesting and immunoselection of patient stem cells from bone marrow. The use of Filgrastim to mobilize large numbers of haematopoietic stem and progenitor cells (HSPC) in the circulation has been associated with severe adverse events in sickle cell patients. Thus, broader application of the gene therapy approach requires the development of alternative mobilization methods. We set up a Phase I/II clinical trial whose primary objective was to assess the safety of a single injection of Plerixafor in sickle cell patients under RBC exchanges to decrease Haemoglobin S level below 30%. The secondary objective was to measure the efficiency of HSPC mobilization and isolation. No adverse events were observed. Large numbers of CD34+ cells were mobilized extremely quickly. Importantly, the mobilized cells contained high numbers of haematopoietic stem cells, expressed high levels of stemness genes, and engrafted very efficiently in immunodeficient mice. Thus, Plerixafor can be safely used to mobilize haematopoietic stem cells in sickle cell patients; this finding opens up new avenues for treatment approaches based on gene addition and genome editing.

9 April 2020 in Blood
Verified
Journal Article
Open access
PDF file
ESEmmanuelle Six
Emmanuelle Six
AGAgathe Guilloux
Agathe Guilloux
ADAdeline Denis
Adeline Denis
ALArnaud Lecoules
Arnaud Lecoules
AMAlessandra Magnani
Alessandra Magnani
FBFrederic D. Bushman
Frederic D. Bushman
In gene therapy with human hematopoietic stem and progenitor cells (HSPCs), each gene-corrected cell and its progeny are marked in a unique way by the integrating vector. This feature enables lineages to be tracked by sampling blood cells and using DNA sequencing to identify the vector integration sites. Here, we studied 5 cell lineages (granulocytes, monocytes, T cells, B cells, and natural killer cells) in patients having undergone HSPC gene therapy for Wiskott-Aldrich syndrome or β hemoglobinopathies. We found that the estimated minimum number of active, repopulating HSPCs (which ranged from 2000 to 50 000) was correlated with the number of HSPCs per kilogram infused. We sought to quantify the lineage output and dynamics of gene-modified clones; this is usually challenging because of sparse sampling of the various cell types during the analytical procedure, contamination during cell isolation, and different levels of vector marking in the various lineages. We therefore measured the residual contamination and corrected our statistical models accordingly to provide a rigorous analysis of the HSPC lineage output. A cluster analysis of the HSPC lineage output highlighted the existence of several stable, distinct differentiation programs, including myeloid-dominant, lymphoid-dominant, and balanced cell subsets. Our study evidenced the heterogeneous nature of the cell lineage output from HSPCs and provided methods for analyzing these complex data.

4 June 2015 in Blood
Verified
Journal Article
Closed access
PDF file
FTFabien Touzot
Fabien Touzot
DMDespina Moshous
Despina Moshous
RCRita Creidy
Rita Creidy
BNBénédicte Neven
Bénédicte Neven
PFPierre Frange
Pierre Frange
MCMarina Cavazzana
Marina Cavazzana
Key Points: SCID-X1 patients treated with gene therapy show faster T-cell development compared with patients treated with haploidentical HSCT.